bxcl501
Generic: dexmedetomidine·Code: BXCL501
bxcl501: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | Phase 3 |
FDA Decisions
FDA_MeetingFDA provided positive pre-sNDA comments; company believes the planned sNDA package is sufficient to support submission and remains on track for Q1 2026.(BTAI)
Frequently asked questions
Who is developing bxcl501?
bxcl501 is being developed by BioXcel Therapeutics, Inc..
What is bxcl501's latest FDA decision?
The most recent tracked FDA decision for bxcl501 is FDA_Meeting for FDA provided positive pre-sNDA comments; company believes the planned sNDA package is sufficient to support submission and remains on track for Q1 2026., dated August 14, 2025.
Get deeper analysis on bxcl501
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis